Centene appointed Paul Diaz to its Board effective July 28, 2026, filling the vacancy created by Kenneth Burdick's resignation.
| IndividualKenneth BurdickPaul Diaz | RoleDirector; member, Quality and Compliance CommitteeDirector; member, Audit Committee and Quality and Compliance Committee | Type of ChangeResignedElected | Effective DateJuly 28, 2026July 28, 2026 | ReasonNot the result of any dispute or disagreement with the Company or the BoardTo fill vacancy created by Mr. Burdick's resignation | Replacement InfoReplaced by Paul DiazN/A | Background DetailsNot disclosedManaging Partner at Cressey & Company since May 2025; former Director, President & CEO of Myriad Genetics (Aug 2020–Apr 2025); prior partner at Cressey (2016–2020); former President & CEO and director at Kindred Healthcare (President & CEO 2004–2015; director 2004–2018) | Board/Committee Role ChangesResigned from Quality and Compliance CommitteeAppointed to Audit Committee and Quality and Compliance Committee |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.